ERBB2 and breast cancer: MiR-221 is implicated in trastuzumab resistance of the HER2 -positive breast cancer cell line by targeting PTEN. On the other hand, the PTEN overexpression reversed the trastuzumab resistance in breast cancer cells and suppressed their invasion capacities [213].